Table 13.
Survey.
| Country | Total number mutations | Novel Unique mutations | Novel Shared mutations | Sum novel mutations | Prevalent mutations | C to T transitions [in % of mutants] | RNA replication | Spike glycoprotein | Nucleocapsid phosphoprotein | COVID‐19 cases | COVID‐19 deaths |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United Kingdom | 43 | 20 | 18 | 38 (88.4%) | 5 | 53.6 | 8 | 6 | 4 | 3,617,459 | 97,329 (2.69%) |
| South Africa | 28 | 9 | 12 | 21 (75%) | 7 | 48.1 | 4 | 7 | 3 | 1,404,839 | 40,574 (2.89%) |
| United States | 39 | 17 | 13 | 30 (76.9%) | 7 | 61.5 | 13 | 3 | 7 | 25,546,140 | 427,294 (1.67%) |
| India | 23 | 9 | 9 | 18 (78.3%) | 5 | 65.2 | 6 | 4 | 2 | 10,655,435 | 153,376 (1.44%) |
| Brazil | 9 | 2 | 2 | 4 (44.4%) | 5 | 44.4 | 1 | 2 | 2 | 8,816,254 | 216,445 (2.46%) |
| Russia | 10 | 3 | 1 | 4 (40%) | 6 | 50 | 2 | 1 | 1 | 3,698,273 | 68,971 (1.86%) |
| France | 27 | 0 | 20 | 20 (74.1%) | 7 | 40.7 | 7 | 2 | 5 | 3,035,181 | 72,877 (2.40%) |
| Spain | 20 | 6 | 10 | 16 (80%) | 4 | 50 | 3 | 4 | 3 | 2,603,472 | 55,441 (2.13%) |
| Germany | 33 | 11 | 15 | 26 (78.8%) | 7 | 51.5 | 5 | 5 | 5 | 2,137,689 | 52,536 (2.46%) |
| People’s Republic of China | 7 | 0 | 2 | 2 (28.6%) | 5 | 57.1 | 1 | 1 | 1 | 88,911 | 4,635 (5.21%) |
The rise of new SARS‐CoV‐2 mutations in many countries was juxtaposed to the high COVID‐19 incidence values around the world. The mutants and their frequencies compiled and calculated in this Table were based on the data presented in Tables 3 and 4A to 12A. World incidence of COVID‐19, as of January 30, 2021, in 219 countries was COVID‐19 cases—102,87 million, fatalities—2.22 million (columns 10 and 11). Column 5 lists the total of novel mutations for each country, percentage values related this sum to the total number of mutations. Source for worldwide spread of COVID‐19—https://www.worldometers.info/coronavirus/.
The UK data in this Table do not contain results from the analysis of the SARS‐CoV‐2 variant B.1.1.7 which are shown in Table 1, as of April 01, 2021.